13 September 2019
EMA/COMP/437105/2019
Inspections, Human Medicines Pharmacovigilance and Committees Division

# Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation

September 2019

The Committee for Orphan Medicinal Products held its 214th plenary meeting on 10-12 September 2019.

## Orphan medicinal product designation

### Positive opinions

The COMP adopted 16 positive opinions recommending the following medicines for designation as orphan medicinal products to the European Commission:

1. Opinions adopted at the second COMP discussion, following the sponsor's response to the COMP list of questions:

- 18-(p-($^{131}$I)-iodophenyl) octadecyl phosphocholine for treatment of multiple myeloma, Voisin Consulting S.A.R.L.;
- 4-oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide for treatment of soft tissue sarcoma, Boyd Consultants Limited;
- Anti-neonatal Fc receptor human monoclonal antibody for prevention of haemolytic disease of the foetus and newborn (HDFN), Biopharma Excellence GmbH;
- Autologous CD34+ haematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the *BCL11A* gene for treatment of beta-thalassaemia intermedia and major, Vertex Pharmaceuticals (Ireland) Limited;
- Besilesomab for treatment in haematopoietic stem cell transplantation, Therapharm Deutschland GmbH;
- Nirogacestat for treatment of soft tissue sarcoma, Voisin Consulting S.A.R.L.;
- Paclitaxel for treatment of soft tissue sarcoma, Boyd Consultants Limited;

**Official address** Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
**Address for visits and deliveries** Refer to www.ema.europa.eu/how-to-find-us
**Send us a question** Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

- Pemigatinib for treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2, Incyte Biosciences Distribution B.V.

2. Opinions adopted at the first COMP discussion:

- (16E)-14-methyl-20-oxa-5,7,14,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene–citric acid for treatment of glioma, Clinical Network Services (NL) B.V.;
- (S)-2-isobutyrylamino-pentanedioic acid 5-amide 1-{[(2S,5S,8S,11R,12S,15S,18S,21R)-2,8-bis-((S)-sec-butyl)-21-hydroxy-5-(4-hydroxy-benzyl)-15-isobutyl-4,11-dimethyl-3,6,9,13,16,22-hexaoxo-10-oxa-1,4,7,14,17-pentaaza-bicyclo[16.3.1]docos-12-yl]-amide} for treatment of Netherton syndrome, MDC RegAffairs GmbH.;
- 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide-methane sulfonic acid salt for treatment of graft-versus-host disease, Quality Regulatory Clinical Ireland Limited;
- 2'-O-(2-methoxyethyl)-D-ribose antisense oligonucleotide targeting glial fibrillary acidic protein messenger ribonucleic acid for treatment of Alexander disease, Ionis Development (Ireland) Limited;
- Combination of two adeno-associated viral vectors of serotype 8 containing the 5'- and the 3'- half coding sequences of human *ABCA4* fused to inteins for treatment of Stargardt's disease, Fondazione Telethon;
- Leriglitazone for treatment of Friedreich's ataxia, Minoryx Therapeutics S.L.;
- Lonapegsomatropin for treatment of growth hormone deficiency, Ascendis Pharma Endocrinology Division A/S;
- Propranolol hydrochloride for treatment of retinopathy of prematurity, Recordati Rare Diseases.

3. Opinion following appeal procedures:

None

Public summaries of opinions will be available on the EMA website following adoption of the respective decisions on orphan designation[1] by the European Commission. Please also refer to the Community Register of orphan medicinal products for human use.

## Negative opinion

1. Opinion(s) adopted following the sponsor's response to the COMP list of questions:

- Melatonin, sorafenib for treatment of hepatocellular carcinoma, Worphmed S.r.l.

2. Opinion following appeal procedures:

None

## Lists of questions

The COMP adopted 10 lists of questions on initial applications. These applications will be discussed again at the next COMP meeting prior to the adoption of an opinion.

[1] Details of all orphan designations granted to date by the European Commission are entered in the EU Register of Orphan Medicinal Products

### Oral hearings

10 oral hearings took place.

### Withdrawals of applications for orphan medicinal product designation

The COMP noted that 7 applications for orphan medicinal product designation were withdrawn by the sponsor before adoption of the COMP opinion.

### Detailed information on the orphan designation procedures

The list of medicinal products for which decisions on orphan designation have been granted by the European Commission since the last COMP meeting is provided in Annex 1.

## Re-assessment of orphan designation at time of marketing authorisation

(Article 5(12) (b) of Regulation (EC) No 141/2000 of the European Parliament and of the Council)

When a designated orphan medicinal product receives a positive opinion for marketing authorisation from EMA's Committee for Medicinal Products for Human Use (CHMP), the COMP has the responsibility to review whether or not the medicinal product still fulfils the designation criteria prior to the granting of a marketing authorisation.

1. Opinions adopted at time of CHMP opinion:

None

2. Opinion following appeal procedures:

None

Details of the designated orphan medicinal products that have been subject of a new European Union (EU) marketing authorisation application since the last COMP monthly report are provided in Annex 2.

Details on the authorised orphan medicinal products can be found on the EMA website.

## Other matters

The main topics addressed during the meeting related to:

- Protocol assistance advice

## Upcoming meetings

- The 215th meeting of the COMP will be held on 8-10 October 2019.

**Note**

This monthly report, together with other information on the work of the European Medicines Agency, can be found on the EMA website: www.ema.europa.eu

**Contact details of our press officer**

Monika Benstetter

Tel. +44 (0)20 3660 8427

E-mail: press@ema.europa.eu

# Annex 1

**Designations granted by the European Commission following COMP opinion on the fulfilment of the orphan designation criteria since last COMP plenary meeting**

Please also refer to the Community Register of orphan medicinal product for human use.

The list includes designation decisions that were revised following the amendment of an existing designated condition (identified by * when applicable)

| Active substance | Orphan indication | Sponsor | COMP opinion date | EC designation date |
|---|---|---|---|---|
| 7-ethyl-10-hydroxycamptothecin | Treatment of soft tissue sarcoma | Cebiotex S.L. | 20 June 2019 | 25 July 2019 |
| 2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one | Treatment of myelodysplastic syndromes | Aprea Therapeutics AB | 20 June 2019 | 25 July 2019 |
| Elafibranor | Treatment of primary biliary cholangitis | Genfit | 20 June 2019 | 25 July 2019 |
| Mavorixafor | Treatment of WHIM syndrome | Voisin Consulting S.A.R.L. | 20 June 2019 | 25 July 2019 |
| N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide | Treatment of neurofibromatosis type 1 | Voisin Consulting S.A.R.L. | 20 June 2019 | 25 July 2019 |
| Parsaclisib | Treatment of marginal zone lymphoma | Incyte Biosciences Distribution B.V. | 20 June 2019 | 25 July 2019 |
| Pevonedistat | Treatment of acute myeloid leukaemia | Takeda Pharma A/S | 20 June 2019 | 25 July 2019 |
| Recombinant mutated extracellular domain of the human acetylcholine receptor subunit alpha1 | Treatment of myasthenia gravis | Toleranzia AB | 20 June 2019 | 25 July 2019 |
| 1-(2,2-diphenyltetrahydrofuran-3-yl)-N,N-dimethylmethanamine hydrochloride | Treatment of Rett syndrome | Anavex Germany GmbH | 18 July 2019 | 21 August 2019 |
| 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine | Treatment of congenital adrenal hyperplasia | Neurocrine Therapeutics Ltd | 18 July 2019 | 21 August 2019 |

| Active substance | Orphan indication | Sponsor | COMP opinion date | EC designation date |
|---|---|---|---|---|
| Acetazolamide | Treatment of periodic paralysis | Laboratorios Tillomed Spain, S.L.U | 18 July 2019 | 21 August 2019 |
| Adenoviral vector serotype 5 encoding the human interleukin-12 p70 transgene under the control of activator ligand veledimex | Treatment of glioma | Ziopharm Oncology Limited | 18 July 2019 | 21 August 2019 |
| Clofazimine | Treatment of nontuberculous mycobacterial lung disease | Dr Sebastian Canisius | 18 July 2019 | 21 August 2019 |
| Gallium citrate | Treatment of cystic fibrosis | Clinical Network Services (NL) B.V. | 18 July 2019 | 21 August 2019 |
| Peginterferon lambda-1a | Treatment of hepatitis D virus infection | Eiger Biopharmaceuticals Europe Limited | 18 July 2019 | 21 August 2019 |
| Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-hydroxy-,15,15'-diester with N-acetyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-alpha-aspartyl-L-tryptophylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-L-threonyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-N6-carboxy-L-lysinamide cyclic (2.fwdarw.12)-(disulfide); where two identical synthetic peptide domains are covalently linked at the ends of the polyethylene glycol chain | Treatment of C3 glomerulopathy | Apellis Ireland Limited | 18 July 2019 | 21 August 2019 |
| Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN6 gene | Treatment of neuronal ceroid lipofuscinosis | Amicus Therapeutics Europe Limited | 18 July 2019 | 21 August 2019 |
| Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene | Treatment of neuronal ceroid lipofuscinosis | Amicus Therapeutics Europe Limited | 18 July 2019 | 21 August 2019 |
| Relacorilant | Treatment of pancreatic cancer | Granzer Regulatory Consulting & Services | 18 July 2019 | 21 August 2019 |
| Setmelanotide | Treatment of Bardet-Biedl syndrome | TMC Pharma (EU) Limited | 18 July 2019 | 21 August 2019 |
| Temozolomide | Treatment of neuroblastoma | ORPHELIA Pharma SAS | 18 July 2019 | 21 August 2019 |

| Active substance | Orphan indication | Sponsor | COMP opinion date | EC designation date |
|---|---|---|---|---|
| Veledimex | Treatment of glioma | Ziopharm Oncology Limited | 18 July 2019 | 21 August 2019 |

# Annex 2

**Designated orphan medicinal products that have been subject of a new European Union marketing authorisation application under the centralised procedure since the last COMP monthly report**

Please also refer to the Community Register of orphan medicinal products for human use.

| Active substance | Designated orphan indication | Sponsor/applicant | EU designation number |
|---|---|---|---|
| Amikacin | Treatment of nontuberculous mycobacterial lung | Insmed Netherlands B.V. | EU/3/14/1259 |
| Givosiran | Treatment of acute hepatic | Alnylam Netherlands B.V. | EU/3/16/1731 |